AXQ Capital LP Has $1.05 Million Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• AXQ Capital cut its Thermo Fisher position by 67.2% in the second quarter, ending with 2,104 shares valued at approximately $1.05 million. Institutional investors collectively own 89.23% of TMO.
• Thermo Fisher reported quarterly adjusted EPS of $6.03, beating estimates of $5.71, while revenue rose 10.5% year over year to $11.99 billion. The company set fiscal 2026 EPS guidance at $24.93–$25.33.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and a $619.41 price target. Thermo Fisher also declared a quarterly dividend of $0.47 per share, equivalent to a 0.3% yield.

AXQ Capital LP decreased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 67.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,104 shares of the medical research company's stock after selling 4,305 shares during the period. AXQ Capital LP's holdings in Thermo Fisher Scientific were worth $1,055,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. Brighton Jones LLC increased its holdings in shares of Thermo Fisher Scientific by 28.9% during the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock worth $2,293,000 after purchasing an additional 988 shares during the period. Revolve Wealth Partners LLC lifted its position in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after acquiring an additional 20 shares during the period. Darwin Wealth Management LLC bought a new position in shares of Thermo Fisher Scientific in the second quarter worth $170,000. Raymond James Financial Inc. grew its stake in Thermo Fisher Scientific by 7.4% during the second quarter. Raymond James Financial Inc. now owns 778,822 shares of the medical research company's stock worth $315,781,000 after buying an additional 53,542 shares in the last quarter. Finally, California State Teachers Retirement System raised its position in shares of Thermo Fisher Scientific by 0.4% in the 2nd quarter. California State Teachers Retirement System now owns 602,031 shares of the medical research company's stock valued at $244,099,000 after buying an additional 2,262 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $629.27, for a total transaction of $6,292,700.00. Following the transaction, the chief executive officer owned 123,925 shares of the company's stock, valued at $77,982,284.75. This represents a 7.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael D. Shafer sold 25,500 shares of the business's stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total value of $15,300,000.00. Following the completion of the sale, the executive vice president directly owned 20,994 shares of the company's stock, valued at $12,596,400. The trade was a 54.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 73,768 shares of company stock valued at $44,122,820 over the last 90 days. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Trading Down 0.9%

TMO opened at $612.75 on Friday. The stock has a market cap of $226.56 billion, a PE ratio of 32.96, a price-to-earnings-growth ratio of 2.57 and a beta of 0.85. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The company has a fifty day moving average of $570.91 and a 200-day moving average of $515.10. Thermo Fisher Scientific Inc. has a twelve month low of $435.27 and a twelve month high of $647.00.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The company had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. During the same quarter in the prior year, the company earned $4.28 EPS. The firm's revenue for the quarter was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific's payout ratio is presently 10.11%.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on TMO shares. Morgan Stanley lifted their price target on Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an "overweight" rating in a research note on Friday, July 24th. Jefferies Financial Group reaffirmed a "buy" rating and issued a $630.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, July 23rd. Royal Bank Of Canada lifted their target price on Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a "sector perform" rating in a research report on Friday, July 24th. Evercore set a $570.00 target price on shares of Thermo Fisher Scientific in a report on Monday, July 6th. Finally, Barclays raised their price objective on Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an "overweight" rating in a report on Friday, July 24th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $619.41.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.